#GDR - The investment case is a simple - testing will be required for years to come - this isn’t a seasonal flu - many companies will continue to generate revenue from the requirements of testing for Coronavirus & its a huge market place that can & will be shared by many.

#GDR - Nearest term SP driver is the imminent shift of the overhang that has been holding us back - when the overhang churns it’ll rise freely and retest recent £3 highs imo - volume is king and last week we surpassed 10m from Weds to Friday - another 10m odd & we are off imo.

#GDR - I am in no way saying the companies are like for like however - at this stage of the cycle #GDR is very much like #NCYT post CE mark - why I say this is because Genedrive have yet to receive their FDA EUA approval & WHO approval - so that’s 2 immediate near term SP drivers

#GDR - SALES - we have global distribution networks already in place with the likes of Sysmex to target areas such as India & Africa - Mr Budd stated in many words in his interviews that our distribution partners have our products & have sent samples to prospective buyers.

#GDR - We are backed by a global powerhouse of a Pharma in the form of Cytiva - who were responsible for the most FDA approvals in 2018 - manufacturing capacity is 10k tests per hour - some back of the fag packet calcs below...

#GDR - 10k kits on a 12 hour shift basis over 7 days = 840k tests. £8-£10 per test so let’s say £9 = £7.56m of which 50-60% profit margins so let’s say 55%... that gives us a profit of approx £4.2m per WEEK or £16.8m per MONTH - note PROFIT not revenue -

#GDR - if it is around the clock production on a 24 hour basis then £8.4m per WEEK or £33.6m per MONTH. Again I stress this is PROFIT not revenue. Given that the current MCAP is shy of £75m - basic number crunching shows why we can & WILL become a company valued at £250m+ MCAP.

#GDR - As ever DYOR - everything stated above is in the public domain & at present #GDR remains one of the most undervalued plays out there when considering the plethora of newsflow/revenue/profits/collaborations - yet to come.

#GDR - Sales expected from June - so Monday - Mr Budd didn’t go on a PR drive to just inform retail PIs - Nope - it was a form of free advertising & utilising platforms out there that other companies have in order to spread awareness of our product for increased enquiries imo.

#GDR - Do the research - load up & reap the rewards - #NCYT early doors £2 was called & most laughed at it - when £2 fell the target was upped to £5 which similarly was breached - #GDR will play out the same damn way & you will regret not taking a look in.

#GDR - Clear cut road map to multibags - FDA approval & WHO approval - further collaborations & finally sales with a hugely attractive profit margin - I rode this from 25p to near £3 on the last go - reentered here at 145p & added upto 186p - will be adding further tomorrow

#GDR - The endgame here is £3 in the next fortnight then onto £5 within the next 4/6 weeks... these are very reserved targets taking into consideration all the metrics associated on the lower end of the spectrum of potential upside - research & conviction is the key to success.

#GDR - https://www.thearmchairtrader.com/genedrive-lse-gdr-stock-rally-has-legs/

#GDR - A must listen - note the bits where David highlights the USP - These are the features of our Antigen test which differentiate us from the competition & will ensure us a substantial market share in the #coronavirus testing space - https://www.proactiveinvestors.co.uk/companies/amp/news/920677?__twitter_impression=true

#GDR - Excellent T/A analysis by no other than @confluencetradr - targets align with those based on fundamentals too https://twitter.com/confluencetradr/status/1267166228692508672?s=21 https://twitter.com/confluencetradr/status/1267166228692508672

#GDR - Overhang is providing an entry here but for how long - may be churned within the first hour tomorrow or it’ll be the day after or it’ll be the backend of this week BUT no one knows for sure - it’s not a dice worth rolling - waiting for lower will lead to chasing higher.